Robust order book does not necessarily mean large orders. Ascendiant forecasts sequential growth QoQ, but not significant. What could change that of course is cearance of spinal products which I believe requires a partnership as Sintx does not have much in the way of spinal sales department anymore. They could use CTL as their partner but the fact they highlight that there is a noncompete clause that ends soon (Oct) in the May presentation, suggests something else. But what do I know.
Market Data 
Markets 
